CPC A61K 39/245 (2013.01) [A61K 39/12 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/5256 (2013.01); A61K 2039/70 (2013.01); C12N 2710/16122 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/24143 (2013.01); C12N 2799/023 (2013.01); C12N 2800/204 (2013.01)] | 13 Claims |
1. A method for treating a CMV infection in a subject comprising: administering to the subject a therapeutically effective amount of a CMV vaccine, and a pharmaceutically acceptable carrier, adjuvant, additive or combination thereof,
wherein the CMV vaccine comprises a modified vaccinia Ankara (MVA) viral vector expressing a set of five CMV proteins or antigenic fragments thereof that form a UL128 complex,
thereby treating the CMV infection in the subject.
|